Inhibikase Therapeutics (IKT) EV/EBIT: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.99-0.01 (-0.50%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Inhibikase Therapeutics, Inc. (IKT)	$262.75M	N/A	N/A	N/A	N/A
Anika Therapeutics, Inc. (ANIK)vs ›	$261.90M	N/A	6.80x	6.80x	39.86x
Century Therapeutics, Inc. (IPSC)vs ›	$260.75M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$260.75M	N/A	11.31x	11.31x	15.93x
AC Immune S.A. (ACIU)vs ›	$260.54M	N/A	17.57x	14.15x	16.75x
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$266.17M	N/A	N/A	N/A	N/A
Lexeo Therapeutics, Inc. Common Stock (LXEO)vs ›	$255.98M	N/A	N/A	N/A	N/A
Indaptus Therapeutics, Inc. (INDP)vs ›	$272.91M	N/A	N/A	N/A	N/A
Invivyd, Inc. (IVVD)vs ›	$249.41M	N/A	N/A	N/A	N/A
Aurora Cannabis Inc. (ACB)vs ›	$276.26M	N/A	15.89x	15.15x	15.15x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

Inhibikase Therapeutics, Inc. (IKT)

$262.75M

N/A

Anika Therapeutics, Inc. (ANIK)vs ›

$261.90M

N/A

6.80x

39.86x